Regentis Biomaterials Raises $15 million for Pivotal US Clinical Trial

Regentis Biomaterials Ltd. reported the closing of its Series D investment round on February 5, 2016.
According to the press release:

The $15 million investment was led by Haisco Pharmaceutical Group (“Haisco”), a leading Chinese pharmaceutical manufacturer, and was joined by existing Regentis investors including Medica Partners, SCP Vitalife Partners, Generali Financial Holdings and both the Technion Research & Development Foundation and the Technion Innovation Opportunities Fund.

According to Alastair Clemow, Ph.D., Regentis Biomaterial’s CEO:

We look forward to collaborating with Haisco to expand the potential of this technology in the Chinese market over the coming years.

Click here to view the full press release.